NJ Weight Loss & Preventive Care

Common Peptide Dosing Protocols

This is not medical advice. This is educational. Every patient that is prescribed peptides from their doctor will receive individualized instructions. This does not constitute an offer to purchase any type of medication.

← GLP-1 Medications (Semaglutide & Tirzepatide)
Verified Sourcing All medications come from FDA-registered U.S. pharmacies. Clinical supplies and select medications ship directly from major licensed distributors like McKesson and Henry Schein — the same wholesalers that supply hospitals and physician offices.
📄 Download PDF version

GLP-1 Medications

A Patient Education Guide: How They Work, What to Expect, and What to Consider

1. What Are GLP-1 Medications, and How Do They Work?

GLP-1 medications have become one of the most significant developments in weight management and metabolic health in recent years. Understanding how they work — and how the different types differ — helps explain why some patients respond differently to each option.

How GLP-1 Medications Work

GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally produces in the gut after eating. Naturally-occurring GLP-1 does several things: it signals your brain that you're full, slows down how quickly your stomach empties, and helps your pancreas release the right amount of insulin in response to food.

GLP-1 medications are designed to mimic and amplify this natural hormone, but with a much longer-lasting effect than your body's own GLP-1 (which breaks down within minutes). By activating GLP-1 receptors continuously, these medications produce sustained appetite suppression, slower digestion, and improved blood sugar regulation — which is why they were originally developed for type 2 diabetes before their weight-loss effects became widely recognized.

The Two Main Types

Semaglutide (Ozempic, Wegovy)

Semaglutide was the medication that brought this drug class into mainstream awareness. It works as a single-mechanism GLP-1 receptor agonist — meaning it activates only the GLP-1 receptor pathway. It remains highly effective for many patients and has the longest track record of real-world use among this newer generation of medications.

Tirzepatide (Mounjaro, Zepbound)

Tirzepatide takes things a step further by activating two receptor pathways instead of one: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone involved in insulin regulation and fat metabolism. This dual-agonist approach is part of why tirzepatide often produces greater average weight loss than semaglutide, and why some patients who plateau on semaglutide see renewed results when switching to tirzepatide.

The Bigger Picture

Each additional receptor pathway — from one (semaglutide) to two (tirzepatide) — represents an attempt to hit more of the body's natural metabolic signaling systems at once. In general, this has correlated with greater average weight loss across the class, but it also means more variables to consider around side effects, cost, and how established the safety data is for each option.

2. Why GLP-1 Medications Sometimes “Suddenly Stop Working”

Patients often assume they got a bad batch when their GLP-1 medication stops producing appetite suppression or weight loss effects after months of steady results. In most cases, what's actually happening is receptor adaptation, not a defective product.

The Mechanism

GLP-1 receptor agonists work by binding to and activating GLP-1 receptors in the brain (hypothalamus) and gut. At a fixed dose, the body's receptors can downregulate over time — becoming less responsive to the same concentration of drug. Early on, a 1 mg dose might fully saturate and activate enough receptors to produce strong appetite suppression. But as the body adapts, that same 1 mg dose no longer produces the same signal — not because the drug degraded, but because the receptor response threshold shifted.

Why It Feels Sudden Rather Than Gradual

Receptor sensitivity often doesn't decline in a smooth, linear fashion — it can behave more like a threshold effect. The patient feels normal appetite suppression right up until the point where remaining receptor activation drops below what's needed to produce a noticeable clinical effect. From the patient's perspective, this shows up as “it worked fine last week and now it's like I'm not taking anything,” which understandably reads as a supply or quality problem rather than a pharmacodynamic one.

Why the Dose Ceiling Matters

The approved maximum doses (2.4 mg for semaglutide, higher tiers for tirzepatide) exist precisely because this adaptation is expected. A patient plateauing at 1 mg still has significant room — more than double — before they've exhausted the dosing range. Titrating up is the standard, evidence-based response to a plateau; it isn't a sign of drug failure.

The Behavioral Trap

Because “bad batch” feels like a supply-chain problem, patients often respond by switching pharmacies or suppliers rather than revisiting their dose with their prescriber. This can lead to unnecessary compounding-pharmacy shopping, delays in care, and in some cases abandoning an otherwise effective medication entirely — when the actual fix is a routine dose adjustment within the approved range.

3. Muscle Loss and Premature Aging: The Overlooked Side Effect of Weight Loss

Losing weight and losing muscle often happen together — and muscle loss is what quietly ages you, both in function and in appearance.

The Muscle Problem

Aggressive dieting, especially without enough protein or resistance training, burns through lean muscle along with fat. This adds to a process already underway: starting around age 20, everyone experiences sarcopenia, a gradual, ongoing decline in muscle mass and strength that continues for decades and has been formally recognized as a disease (ICD-10 code M62.84). Combine natural sarcopenia with diet-driven muscle loss, and by their 50s, many patients have lost far more muscle than they realize — leaving them lighter on the scale but weaker and less resilient than they were years earlier.

The Documented Link to Mobility and Longevity

This isn't just a cosmetic concern — it's well established in the medical literature:

  • A meta-analysis spanning over 42,000 participants across multiple studies confirmed sarcopenia's association with mortality across community-dwelling adults, outpatients, inpatients, and nursing home residents.
  • A large Chinese cohort study found that sarcopenia was associated with meaningfully higher odds of death over 7 years of follow-up, with the risk more than doubling for severe sarcopenia — and the relative mortality risk was actually highest in the 45–60 age group.
  • Research on hospitalized elderly patients found that sarcopenia was significantly associated with higher mortality specifically among patients with limited mobility and degraded functional abilities, regardless of age. Among those with lower autonomy scores, the risk of death was up to 3.63 times higher in sarcopenic patients.
  • A longitudinal study using Chinese health data set out to estimate sarcopenia-specific life expectancy, noting sarcopenia's well-established association with mortality, falls, physical disability, and poor quality of life.
  • A Japanese population study found sarcopenia carried more than double the hazard of all-cause mortality compared to those without it, concluding that a public health strategy for sarcopenia is needed to extend healthy life expectancy.

The pattern across this research is consistent: less muscle mass correlates with reduced mobility, greater functional decline, and shorter life expectancy — independent of many other health factors.

Why It Shows Up on Your Face

Muscle loss isn't limited to arms, legs, and core — it affects facial musculature too. The muscle beneath the skin that gives a face its shape and structure diminishes along with muscle everywhere else. This is a major, underappreciated reason people who lose significant weight often look older rather than simply slimmer: without the underlying muscle support, skin appears looser, features appear more sunken, and the face takes on a prematurely aged look.

Where Diet and Exercise Fall Short

Protein intake and resistance training are essential and effective for building and preserving skeletal muscle — but they have limited reach into facial muscle and don't directly address the hormonal decline (particularly falling growth hormone levels) that drives much of this aging process from the inside out.

An Option Worth Exploring

Growth hormone-releasing peptides work by stimulating your body's own natural GH production. They're not all FDA-approved for this specific use, and the evidence varies by peptide — but interest has grown rapidly, with tens of thousands of people across TikTok, YouTube, Reddit, and Facebook reporting visible improvements in muscle tone, facial fullness, and overall youthfulness.

Curious if this is right for you? Contact a member of our staff for a personalized assessment.

4. Thinking About Switching GLP-1 Medications? Things to Consider

If your current medication has stopped working, or side effects are becoming difficult to manage, you may be exploring your options. Here's what's worth knowing about the path from semaglutide (Ozempic/Wegovy) to tirzepatide (Mounjaro/Zepbound).

Semaglutide (Ozempic/Wegovy)

This is often the starting point. If it worked well for a period of time and then plateaued, that's frequently a dosing issue rather than a reason to switch medications entirely — many patients find success simply titrating up before considering a different drug.

Tirzepatide (Mounjaro/Zepbound)

This is a reasonable next step when:

  • Semaglutide has genuinely stopped producing results even at higher doses
  • Side effects on semaglutide (nausea, GI upset) are becoming intolerable rather than mild, and adjusting the dose hasn't helped
  • You've discussed with your provider that a dual-mechanism medication may work differently for your body

Newer medications in this class are generally designed with an eye toward improved tolerability, so some patients do experience fewer side effects on tirzepatide even at comparable effectiveness levels — though individual response varies.

On Cost

This is worth factoring in either direction:

  • Newer medications (tirzepatide) tend to carry a higher price tag, at least initially
  • At the same time, semaglutide and tirzepatide prices have both dropped significantly in recent months, which may make “staying the course” with a dose adjustment more attractive than switching, especially if cost is a factor in your decision

The Bottom Line

Whether a plateau, side effects, or something else is driving the conversation, it's worth separating three different questions: is this a dosing problem, a tolerability problem, or a genuine non-response to the mechanism itself? Each points toward a different next step, and working through that with your provider before switching often saves both time and money.

This guide is for general educational purposes and is not a substitute for individualized medical advice. Please consult with a licensed provider to determine the best treatment approach for your specific situation. For questions, use the contact options below.

About This Reference

This information illustrates ideas about dosing as shown in the dosing tables, titration schedules, and stack protocols. These protocols are extremely general in nature and are not meant to be adopted for anyone's use of peptides. This is not medical advice and not reviewed by the FDA.

These were gathered using AI through internet sources, physician YouTube videos, scientific studies, etc. Although these sources seem credible, we cannot take any responsibility for the safety of using any peptides at any dosage for any individual who is not our patient and has not gone through our intake process and had their individual medical history assessed by our clinical team.

It is a companion to the Peptide Therapy Guide — Explanations, which explains in a general way what each peptide is and why it is prescribed. All dosing on this page is a starting reference only; a specific protocol for any patient is determined by Dr. Daniel Olivero, MD and our clinical team.

Important Disclaimer — Read Before Using This Reference

Dosing tables and titration schedules on this page are for reference only, intended for use by licensed prescribers. They are not a substitute for individualized clinical judgment.

This assessment and dosing information is not intended for use by unlicensed individuals or by licensed professionals who lack adequate training and experience in assessing patients for peptide therapy. All clinical decisions and dosing must be made in consultation with a licensed, experienced physician and a licensed, experienced compounding pharmacist, and should be supported by published clinical studies.

The information presented here has been compiled using Artificial Intelligence, statements from videos and websites by apparent qualified professionals, and available published research. We strongly encourage exhaustive independent research before considering any peptide.

Anyone starting a medication they have never taken before should take an extremely conservative approach. Without large-scale, long-term clinical studies, all medications carry the possibility of unknown or unreported side effects. These materials are provided only to help begin your research. They are not medical advice and should not be used as a substitute for professional medical care.

1. How Peptides Are Administered

Most peptide therapies are administered via subcutaneous injection—a small needle just under the skin, typically in the abdomen or thigh. The needles are tiny (30 or 31 gauge insulin syringes) and most patients report minimal discomfort. Some peptides are also available as oral capsules, intranasal sprays, topical creams, or IV/IM injections. All injectable medications include syringes and ship overnight directly from the pharmacy.

Storage & Handling

General Prescribing Principles

2. Stacked Peptide Protocols

Specific peptide combinations—called stacks—can produce synergistic effects that exceed what any single peptide would achieve alone. Your clinical team will recommend the right combination for your individual needs.

Stack Components & Typical Doses Frequency / Cycle Clinical Rationale
Accelerated Healing BPC-157: 250–500 mcg
TB-500: 750 mcg–2.5 mg		 BPC: 1–2x daily
TB-500: 2x/week		 BPC-157 promotes angiogenesis and gut healing; TB-500 drives cell migration and tissue regeneration. Synergistic repair.
Comprehensive Repair & Anti-Inflammatory BPC-157: 250 mcg
TB-500: 1 mg
GHK-Cu: 1–2 mg
KPV: 250 mcg		 BPC daily; TB-500 2x/wk; GHK-Cu daily or 3–5x/wk; KPV daily Full-spectrum healing: repair (BPC/TB), collagen stimulation (GHK-Cu), and targeted inflammation reduction (KPV). Effective for autoimmune-related inflammation and chronic gut issues.
Healing & Gut Inflammation BPC-157: 250 mcg
KPV: 200–500 mcg
TB-500: 1 mg		 All components daily or as directed Streamlined protocol for inflammatory bowel conditions and leaky gut with tissue healing support.
Targeted Fat Loss & GH Tesamorelin: 1–2 mg
Ipamorelin: 200–300 mcg		 Both daily at bedtime Tesamorelin provides sustained GHRH stimulation for visceral fat reduction; Ipamorelin delivers clean GH pulses. Comprehensive body composition improvement.
Metabolic Optimization AOD-9604: 300 mcg
MOTS-c: 5 mg
Tesamorelin: 1 mg		 AOD/Tes daily; MOTS-c 2–3x/week Aggressive metabolic stack targeting fat loss from the fat cell (AOD), mitochondria (MOTS-c), and hormonal axis (Tesamorelin) simultaneously.
Fat Loss & Metabolic Support AOD-9604: 300–600 mcg
MOTS-c: 5–10 mg		 AOD daily; MOTS-c 2–3x/week For patients on GLP-1 wanting additional metabolic support, or those not candidates for GH peptides.
Repair & Rejuvenation BPC-157: 250 mcg
TB-500: 1 mg
GHK-Cu: 1–2 mg		 BPC daily; TB-500 2x/wk; GHK-Cu daily or 3–5x/wk Combines internal healing with visible anti-aging benefits via collagen stimulation.
Anti-Aging & Longevity GHK-Cu: 1–2 mg
Epithalon: 5–10 mg		 Both daily for 10–20 day cycles GHK-Cu supports visible repair; Epithalon activates telomerase for cellular-level longevity.
Cognitive & Neurological Pinealon: 10 mg
PE-22-28: 100–500 mcg
Selank: 250–500 mcg		 All daily; cycle 10–20 days Brain-focused nootropic stack targeting cognitive performance, mental clarity, and stress resilience.

3. Dosing Reference Tables

Important: These are suggested starting points only. All dosing is determined and adjusted by Dr. Daniel Olivero, MD and the clinical team based on each patient's labs, health history, current medications, and treatment goals. Do not self-adjust dosing without physician approval.

GLP-1 & Weight Management Peptides

PeptideRouteSuggested Dose RangeFrequencyNotes
SemaglutideSubQ0.25 mg titrated up to 2.4 mgOnce weeklyTitrate every 4 weeks per tolerance
TirzepatideSubQ2.5 mg titrated up to 15 mgOnce weeklyTitrate every 4 weeks per tolerance

GLP-1 Titration Schedules & Vial Duration

Weeks of Supply = Total mg in Vial ÷ Weekly Dose (mg)

A note on microdosing: Many patients choose to stay at a lower dose than the maximum—sometimes called "microdosing." This approach can help reduce side effects and make each vial last significantly longer. There is no single "right" dose. Work with your healthcare provider to find what works best for you.

Semaglutide Titration

Starting dose: 0.25 mg/week

Vial Size@ 0.25 mg/wk@ 0.5 mg/wk@ 1.0 mg/wk@ 2.0 mg/wk@ 2.4 mg/wk
5 mg20 weeks10 weeks5 weeks2.5 weeks~2 weeks
10 mg40 weeks20 weeks10 weeks5 weeks~4 weeks
15 mg60 weeks30 weeks15 weeks7.5 weeks~6 weeks
20 mg80 weeks40 weeks20 weeks10 weeks~8 weeks
30 mg120 weeks60 weeks30 weeks15 weeks12.5 weeks

Tirzepatide Titration

Starting dose: 2.5 mg/week

Vial Size@ 2.5 mg/wk@ 5 mg/wk@ 7.5 mg/wk@ 10 mg/wk@ 15 mg/wk
5 mg2 weeks1 week~5 days~3.5 days~2.3 days
10 mg4 weeks2 weeks~1.3 weeks1 week~4.7 days
15 mg6 weeks3 weeks2 weeks1.5 weeks1 week
20 mg8 weeks4 weeks~2.7 weeks2 weeks~1.3 weeks
30 mg12 weeks6 weeks4 weeks3 weeks2 weeks
50 mg20 weeks10 weeks~6.7 weeks5 weeks~3.3 weeks

Growth Hormone Support Peptides

PeptideRouteSuggested Dose RangeFrequencyNotes
SermorelinSubQ200–500 mcgDaily at bedtimeCycle 5 days on / 2 days off or as directed
TesamorelinSubQ1–2 mgDailyFDA-approved for visceral fat; empty stomach
CJC-1295 (no DAC) / IpamorelinSubQCJC: 100–300 mcg / Ipa: 200–300 mcg1–3x daily (commonly at bedtime)Empty stomach; no food 30 min after. CJC with DAC is dosed weekly, not daily.
IGF-1 LR3SubQ20–80 mcgDaily (cycle 4–6 wks on, 2–4 off)Potent; monitor blood glucose and IGF-1 levels

Fat Metabolism & Metabolic Peptides

PeptideRouteSuggested Dose RangeFrequencyNotes
AOD-9604SubQ300–600 mcgDaily on empty stomachDoes not raise blood sugar; often combined with MOTS-c
MOTS-cSubQ5–10 mg2–3x per weekMitochondrial peptide; investigational for most uses

Tissue Repair & Recovery Peptides

PeptideRouteSuggested Dose RangeFrequencyNotes
BPC-157SubQ250–500 mcg1–2x dailyInject near injury site when possible; often stacked with TB-500
TB-500 (Thymosin Beta-4)SubQ750 mcg–2.5 mg2x/week (loading), then weeklyLoading phase 4–6 weeks, then maintenance
TB-4 FragmentSubQ200–400 mcgDaily or every other dayTruncated form; similar benefits at lower dose
KPVSubQ / Oral200–500 mcgDailyAnti-inflammatory; especially useful for gut inflammation

Immune Support Peptides

PeptideRouteSuggested Dose RangeFrequencyNotes
Thymosin Alpha-1SubQ1.6 mg2–3x per weekWell-studied; used internationally for chronic infections

Anti-Aging, Skin & Longevity Peptides

PeptideRouteSuggested Dose RangeFrequencyNotes
GHK-CuSubQ / Topical1–2 mg SubQ or topical as directedDaily or 3–5x/weekCollagen stimulation; hair and skin rejuvenation
EpithalonSubQ5–10 mgDaily for 10–20 day cyclesTelomerase activation; cycle 2–3x per year
NAD+IV / SubQIV: 250–500 mg; SubQ: 50–200 mgIV: 1–2x/month; SubQ: 2–3x/weekCoenzyme; supports mitochondrial function and DNA repair

Sexual Health Peptides

PeptideRouteSuggested Dose RangeFrequencyNotes
PT-141 (Bremelanotide)SubQ1–2 mgAs needed, 45 min prior to activityMax 1 dose per 24 hrs; no more than 8 doses/month; may cause flushing/nausea

Cognitive & Neurological Support Peptides

PeptideRouteSuggested Dose RangeFrequencyNotes
CerebrolysinIM / IV5–10 mLDaily for 10–20 day cyclesPorcine-derived; primarily studied in Europe/Asia
SelankIntranasal250–500 mcg1–3x dailyAnxiolytic; no sedation; supports focus and clarity
PinealonSubQ / Oral10–20 mgDaily for 10–20 day cyclesBioregulator; supports sleep and neuroprotection
PE-22-28SubQ / Intranasal100–500 mcgDailyBDNF pathway; investigational antidepressant properties

4. Safety Monitoring & Side Effects

Most side effects are mild and temporary:

Serious side effects are rare with proper dosing and regulated sourcing. If you experience anything unusual, contact our office immediately at (908) 598-0509.

GLP-1 & Dual/Triple Agonist Class Cautions: Contraindicated in personal or family history of medullary thyroid carcinoma or MEN-2. Caution with pancreatitis history, gallbladder disease, severe GI disease, active eating disorders, or pregnancy/planned pregnancy. Patients on insulin or sulfonylureas need dose adjustment to avoid hypoglycemia. Rapid weight loss requires deliberate lean-mass preservation (protein intake + resistance training). Delayed gastric emptying alters absorption of oral medications.
GH-Axis Peptide Cautions (Sermorelin, Tesamorelin, CJC-1295/Ipamorelin, IGF-1 LR3): Screen for cancer history, pituitary disorders, and diabetes/insulin resistance. Monitor for edema, carpal tunnel symptoms, glucose intolerance, and IGF-1 elevation above age-appropriate reference ranges. Reduce or discontinue if these develop. IGF-1 LR3 requires additional glucose monitoring and cancer screening due to sustained IGF-1 signaling without pituitary feedback.
PT-141 Specific Cautions: Bremelanotide can cause transient increases in blood pressure and decrease in heart rate. It should be used cautiously in patients with cardiovascular disease. The most common side effects are nausea (~40%), flushing (~20%), and headache (~11%). Focal hyperpigmentation has been reported with repeated use. Avoid within 24 hours of alcohol.
Tissue-Repair Peptide Cautions (BPC-157, TB-500): Both are on the WADA prohibited list at all times—competitive athletes will fail drug testing. Theoretical concern for pro-angiogenic effects supporting occult tumor growth means cancer history matters. Not a substitute for orthopedic evaluation, imaging, physical therapy, or surgery when those are indicated.
Immune-Modulator Cautions (Thymosin Alpha-1): Caution in autoimmune disease, organ transplant on immunosuppression, pregnancy, severe allergic disease. Immune activation is not always beneficial. Fever, severe fatigue, joint pain, or worsening of autoimmune symptoms require prompt evaluation and discontinuation.
GHK-Cu Cautions: Contraindicated in Wilson's disease and other copper metabolism disorders. Caution with copper/metal allergy, active or recent cancer, and pregnancy. Layering topical GHK-Cu with acidic products or high-concentration vitamin C can destabilize the peptide. Injectable use is investigational and regulatory-sensitive; topical is the well-established first-line route.

5. Regulatory Climate & Making Informed Choices

A Note on the Regulatory Climate

The peptide therapy landscape continues to evolve. Some peptides have full FDA approval. Others are available through licensed compounding pharmacies under current regulations. Still others exist in a regulatory grey area.

We strongly encourage every patient to conduct their own exhaustive research before pursuing any peptide therapy. We do not recommend purchasing peptides from online research-chemical vendors or unverified sources.

We are not anti-pharmaceutical industry. Large pharmaceutical companies have developed many important and life-changing medicines. At the same time, we believe patients benefit from transparency about the full picture — including publicly documented cases of large fines, lawsuits, political contributions, and the movement of officials between regulatory agencies and industry.

Our approach is one of common-sense healthcare choices. We work exclusively with licensed U.S. compounding pharmacies, require medical evaluation and ongoing oversight, and adjust protocols as regulations change.

Third-Party Research Sources

We encourage patients and prescribers to review independent, publicly available reporting on pharmaceutical policy and industry conduct.

6. References & Key Literature

  1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384(11):989-1002. (STEP-1)
  2. Aronne LJ, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity." N Engl J Med. 2025;393:26-36. (SURMOUNT-5)
  3. Stanley TL, et al. "Visceral Fat Reduction with Tesamorelin Is Associated With Improved Liver Enzymes." Analysis of Phase III registration data. PMC. 2018.
  4. Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295." J Clin Endocrinol Metab. 2006;91(3):799-805.
  5. Heffernan M, et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism." Endocrinology. 2001;142(12):5182-9.
  6. Lu H, et al. "MOTS-c: A promising mitochondrial-derived peptide for metabolic disease." PMC. 2022;14:9905433.
  7. Pickart L, et al. "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." PMC. 2014;6:4508379.
  8. Pickart L, et al. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." PMC. 2018;10:6073405.
  9. Comprehensive review of Thymosin alpha-1 literature. PMC. 2020;11:7747025.
  10. TESTS Trial. "The efficacy and safety of thymosin α1 for sepsis." BMJ. 2025;388:e082583.
  11. FDA. NDA 210557 — Vyleesi (bremelanotide) Approval Package. June 2019.
  12. Clayton AH, et al. "Bremelanotide for female sexual dysfunction." Obstet Gynecol. 2019;134(5):1030-1038. (RECONNECT)
  13. Goldstein I, Goldstein S. "Use of Bremelanotide (Vyleesi) in Men with Sexual Dysfunctions." J Sex Med. 2024 (Abstract).
  14. Lee & Padgett. "BPC-157 and TB4 for knee pain." Retrospective study, 2021.
  15. Lee et al. "Intravesicular BPC-157 for interstitial cystitis." Pilot study, 2024.
  16. Lee & Burgess. "IV BPC-157 safety in healthy adults." Pilot study, 2025.
  17. Coskun T, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist." Cell Metab. 2022;34(9):1234-e12479.

The Bottom Line

Before starting any peptide protocol, speak with your prescribing physician. Do your homework. Read about the peptides that interest you. Understand what the evidence supports and where the science is still emerging. An educated patient is a safer patient—and that is exactly what we want for everyone we treat.

Disclaimer
This document is for educational purposes only and does not constitute medical advice. Peptide therapies should only be used under the supervision of a qualified healthcare provider. Some peptides discussed are investigational and not FDA-approved for all described uses. Regulatory status and availability are subject to change. All medications are prepared and dispensed by licensed FDA-registered compounding pharmacies. These statements have not been evaluated by the FDA. Always consult with your medical provider before starting or modifying any treatment protocol.
For peptide explanations, mechanisms of action, and recommended videos, see the Peptide Therapy Guide — Explanations →

NJ Weight Loss & Preventive Care Clinics PA
Physician's Offices: 420 Route 46 East Fairfield NJ 07004 & 1605 E Evesham Road Voorhees NJ 08043
(908) 598-0509  |  Jbock@njweightloss.us